{"id":"NCT02720952","sponsor":"Neurocrine UK Limited","briefTitle":"Treatment of Adrenal Insufficiency in Children","officialTitle":"A Phase 3 Open-label Study of Infacort® in Neonates, Infants and Children Less Than 6 Years of Age With Adrenal Insufficiency","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-03","primaryCompletion":"2016-07","completion":"2016-07","firstPosted":"2016-03-28","resultsPosted":"2017-04-11","lastUpdate":"2022-05-04"},"enrollment":24,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Adrenal Insufficiency"],"interventions":[{"type":"DRUG","name":"Infacort®","otherNames":[]}],"arms":[{"label":"Infacort","type":"EXPERIMENTAL"}],"summary":"The study will be conducted in a total of 24 subjects before their 6th birthday, requiring replacement therapy for adrenal insufficiency due to either CAH, primary adrenal failure or hypopituitarism.\n\nThe study will consist of three consecutive cohorts. Cohort 1 will include 12 subjects aged between 2 and \\< 6 years. If no safety concerns emerge, then 6 subjects aged 28 days to \\<2 years will be enrolled (Cohort 2). A review of accumulated data will be undertaken and only if again no safety concerns emerge, then 6 neonates aged from birth to \\<28 days will be enrolled (Cohort 3).\n\nThe decision to continue after each cohort will be based on the recommendation of an Independent Data Monitoring Committee (IDMC).","primaryOutcome":{"measure":"Serum Cortisol Concentration up to 240 Minutes","timeFrame":"240 minutes","effectByArm":[{"arm":"Infacort","deltaMin":575.8,"sd":47.9}],"pValues":[]},"eligibility":{"minAge":"1 Week","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["Germany"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":24},"commonTop":["Diarrhoea","Vomiting","Rash","Infantile spitting up","Hyperhidrosis"]}}